Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced
“We are pleased to share these updated results from the pivotal portion of the ongoing PYNNACLE trial, which continue to enhance our understanding about the potential of rezatapopt to deliver deep and durable responses in patients with limited targeted treatment options. The improvements in overall response rates and median duration of response across all cohorts and specifically in the ovarian cancer cohort are encouraging and further support the potential of rezatapopt to meaningfully impact outcomes for patients with TP53 Y220C mutated advanced tumors,” said Deepika Jalota, Pharm.D., Chief Development Officer of PMV Pharma. “We remain on track to submit an NDA in the first quarter of 2027 for platinum-resistant/refractory ovarian cancer, while continuing to generate additional data to support our broader regulatory strategy.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data